Get the Stockscreener App
0.304
1.78%
-0.0055
After Hours:
.32
0.016
+5.26%
Athira Pharma Inc stock is traded at $0.304, with a volume of 138.45K.
It is down -1.78% in the last 24 hours and up +8.57% over the past month.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.
See More
Previous Close:
$0.3095
Open:
$0.3002
24h Volume:
138.45K
Relative Volume:
0.26
Market Cap:
$14.06M
Revenue:
-
Net Income/Loss:
$-117.67M
P/E Ratio:
-0.0984
EPS:
-3.09
Net Cash Flow:
$-101.06M
1W Performance:
-15.56%
1M Performance:
+8.57%
6M Performance:
-48.03%
1Y Performance:
-88.08%
1-Day Range:
$0.295
$0.325
1-Week Range:
$0.295
$0.359
52-Week Range:
$0.2195
$3.67
Athira Pharma Inc Stock (ATHA) Company Profile
Name
Athira Pharma Inc
Sector
Industry
Phone
(425) 620-8501
Address
18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL
Compare ATHA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATHA
Athira Pharma Inc
|
0.304 | 14.06M | 0 | -117.67M | -101.06M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
Athira Pharma Inc Stock (ATHA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-19-24 | Downgrade | Mizuho | Outperform → Neutral |
| Sep-04-24 | Downgrade | BTIG Research | Buy → Neutral |
| Sep-04-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Sep-04-24 | Downgrade | Rodman & Renshaw | Buy → Neutral |
| Aug-19-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-17-22 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Jul-07-22 | Initiated | Mizuho | Buy |
| Jun-23-22 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jun-23-22 | Downgrade | Jefferies | Buy → Hold |
| Jun-23-22 | Downgrade | Stifel | Buy → Hold |
| May-10-22 | Initiated | BTIG Research | Buy |
| Apr-21-22 | Initiated | Berenberg | Buy |
| Dec-15-21 | Initiated | Goldman | Neutral |
| Oct-13-20 | Initiated | Goldman | Buy |
| Oct-13-20 | Initiated | JMP Securities | Mkt Outperform |
| Oct-13-20 | Initiated | Jefferies | Buy |
| Oct-13-20 | Initiated | Stifel | Buy |
View All
Athira Pharma Inc Stock (ATHA) Latest News
Two Sigma Advisers LP Has $149,000 Position in Athira Pharma, Inc. (NASDAQ:ATHA) - Defense World
ATHA LOSS ALERT: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Athira Pharma, Inc. Investors with LARGE LOSSES to Secure Counsel Before Important Deadline in Securities Class Action – ATHA - ACCESS Newswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Athira Pharma (NASDAQ:ATHA) Trading 9.2% Higher – Here’s Why - Defense World
HAGENS BERMAN, NATIONAL ATTORNEYS, Alerts Athira Pharma (ATHA) Investors to Filing Of Securities Class Action, Advises Investors with Losses to Contact Firm's Attorneys Now - ACCESS Newswire
Athira Pharma Presents Data from ACT-AD Phase 2 Proof-of-Concept Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Patients at the Alzheimer's Association International Conference 2022 - Barchart.com
Athira Pharma Holds Annual Stockholders Meeting - TipRanks
Athira Pharma Presents Preclinical Data at the Alzheimer's Association International Conference 2022 - Barchart.com
Athira Pharma (ATHA) Is Paying a $10M Settlement to Investors — Here’s How to Get Your Share - TradingView
Athira Pharma’s SWOT analysis: als drug developer’s stock faces pivotal phase - Investing.com
Athira Pharma (ATHA) Highlights Promising Phase 1 Results for ALS Drug Candidate | ATHA Stock News - GuruFocus
Athira Pharma to present data from first-in-human Phase 1 trial of ATH-1105 - Yahoo Finance
Athira Pharma (ATHA) Projected to Post Earnings on Wednesday - Defense World
Athira Pharma Reports Reduced Losses and Strategic Focus - MSN
Athira Pharma to Present Data from First-in-Human Phase 1 Clinic - GuruFocus
Athira Pharma to Present Data from First-in-Human Phase 1 - GlobeNewswire
Breakthrough ALS Drug ATH-1105 Achieves Key Safety Milestones, Targets Patient Trials Late 2025 - Stock Titan
Athira Pharma Reports First Quarter 2025 Financial Results and P - GuruFocus
Athira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business Updates - The Manila Times
Athira Pharma, Inc. (NASDAQ:ATHA) Position Lowered by Renaissance Technologies LLC - Defense World
Athira Pharma Slides As Insider Purchases Lose Another US$89k - simplywall.st
Head-To-Head Review: NKGen Biotech (NYSE:NKGN) and Athira Pharma (NASDAQ:ATHA) - Defense World
ATHAAthira Pharma, Inc. Latest Stock News & Market Updates - Stock Titan
Athira Pharma shifts to Nasdaq Capital Market amid compliance bid By Investing.com - Investing.com India
Athira Pharma shifts to Nasdaq Capital Market amid compliance bid - Investing.com Australia
Athira Pharma stock plunges to 52-week low of $0.25 - Investing.com Australia
Athira Pharma stock plunges to 52-week low of $0.25 By Investing.com - Investing.com South Africa
SEC Form PRE 14A filed by Athira Pharma Inc. - Quantisnow
Athira Pharma stock hits 52-week low at $0.3 amid steep decline - Investing.com India
Athira Pharma stock hits 52-week low at $0.3 amid steep decline By Investing.com - Investing.com South Africa
What is ATHA’s price-to-sales ratio telling us about the company’s value? - US Post News
Athira Pharma: Hold Rating Amid Strategic Uncertainty and Resource Challenges - TipRanks
Athira Pharma stock hits 52-week low at $0.33 amid steep decline - Investing.com India
Athira Pharma stock hits 52-week low at $0.33 amid steep decline By Investing.com - Investing.com South Africa
Athira Pharma Stock Price, Quotes and Forecasts | NASDAQ:ATHA - Benzinga
Athira Pharma’s Strategic Focus on ATH-1105 Amidst Uncertainties: Hold Rating Maintained - TipRanks
Athira Pharma’s 2024 Financial Results and Pipeline Progress - MSN
Athira Pharma Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Athira Pharma Reports Full Year 2024 Financial Results and Pipeline and Business Updates - GlobeNewswire
Athira Pharma, Inc. SEC 10-K Report - TradingView
Athira Pharma stock hits 52-week low at $0.41 amid steep decline - Investing.com Australia
Athira Pharma stock hits 52-week low at $0.41 amid steep decline By Investing.com - Investing.com South Africa
Athira Pharma Inc Stock (ATHA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Athira Pharma Inc Stock (ATHA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| San Martin Javier | CHIEF MEDICAL OFFICER |
Jan 02 '25 |
Sale |
0.56 |
10,826 |
6,083 |
35,841 |
| Litton Mark James | President and CEO |
Dec 31 '24 |
Option Exercise |
0.00 |
108,333 |
0 |
267,698 |
| Litton Mark James | President and CEO |
Jan 02 '25 |
Sale |
0.56 |
25,107 |
14,108 |
242,591 |
| CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER |
Dec 31 '24 |
Option Exercise |
0.00 |
36,667 |
0 |
139,271 |
| CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER |
Jan 02 '25 |
Sale |
0.56 |
8,510 |
4,782 |
130,761 |
| Renninger Robert | VP of Finance |
Dec 31 '24 |
Option Exercise |
0.00 |
12,359 |
0 |
92,605 |
| Renninger Robert | VP of Finance |
Jan 02 '25 |
Sale |
0.56 |
2,881 |
1,619 |
89,724 |
| Worthington Mark | General Counsel and CCO |
Dec 31 '24 |
Option Exercise |
0.00 |
36,667 |
0 |
92,245 |
| Worthington Mark | General Counsel and CCO |
Jan 02 '25 |
Sale |
0.56 |
8,510 |
4,782 |
83,735 |
1.91%
1.17%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):